CliffBio
small molecule

REVERSOL

EDROPHONIUM CHLORIDE

Loss of exclusivity—loss of exclusivity
CompanyOrganon →See this company's full patent-cliff portfolio

Drug detail

Brand nameREVERSOL
Active ingredientEDROPHONIUM CHLORIDE
Strength10MG/ML
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalMay 1988
Marketing statusDISCN

More from Organon

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

REVERSOL patent cliff — loss of exclusivity — | CliffBio